trial summary · NCT06820723
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
Trial record from the TrialBase DB dataset, status RECRUITING, condition Depression, sponsored by Ohio State University. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Source record: https://clinicaltrials.gov/study/NCT06820723
Facts
| registry id | NCT06820723 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Depression |
| sponsor | Ohio State University |
| sponsor class | OTHER |
| enrollment | 40 |
| start date | 2026-11-01 |
| primary completion | 2028-11 |
| completion | 2028-11 |
| results posted | not reported |
Conditions
- Depression
- Anxiety
- Major Depressive Disorder
Interventions
- CYB003
- Placebo
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.